Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.

Kurai J, Chikumi H, Hashimoto K, Takata M, Sako T, Yamaguchi K, Kinoshita N, Watanabe M, Touge H, Makino H, Igishi T, Hamada H, Yano S, Shimizu E.

Int J Oncol. 2012 Nov;41(5):1610-8. doi: 10.3892/ijo.2012.1607. Epub 2012 Aug 24.

2.

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.

Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, Nakamoto M, Burioka N, Shimizu E.

Clin Cancer Res. 2007 Mar 1;13(5):1552-61.

3.

Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.

Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, Nishioka Y.

Cancer Sci. 2016 Sep;107(9):1198-205. doi: 10.1111/cas.12985. Epub 2016 Aug 25.

4.

Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity.

Hara M, Nakanishi H, Tsujimura K, Matsui M, Yatabe Y, Manabe T, Tatematsu M.

Cancer Sci. 2008 Jul;99(7):1471-8. doi: 10.1111/j.1349-7006.2008.00821.x. Epub 2008 Apr 16.

5.

In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.

Hamaguchi N, Hamada H, Miyoshi S, Irifune K, Ito R, Miyazaki T, Higaki J.

Cancer Sci. 2010 Sep;101(9):1955-64. doi: 10.1111/j.1349-7006.2010.01632.x.

6.

Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.

Jänne PA, Taffaro ML, Salgia R, Johnson BE.

Cancer Res. 2002 Sep 15;62(18):5242-7.

7.

Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.

Okita R, Shimizu K, Nojima Y, Yukawa T, Maeda A, Saisho S, Nakata M.

Oncol Rep. 2015 Dec;34(6):2864-70.

8.

SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.

Van TT, Hanibuchi M, Goto H, Kuramoto T, Yukishige S, Kakiuchi S, Sato S, Sakaguchi S, Dat le T, Nishioka Y, Akiyama S, Sone S.

Respirology. 2012 Aug;17(6):984-90. doi: 10.1111/j.1440-1843.2012.02193.x.

PMID:
22574723
9.

A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.

Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, Nishioka Y.

J Immunol. 2013 Jun 15;190(12):6239-49. doi: 10.4049/jimmunol.1300448. Epub 2013 May 20.

10.

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.

Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K.

Cancer Sci. 2007 Aug;98(8):1275-80. Epub 2007 May 13.

11.

GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.

Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P.

Clin Cancer Res. 2013 Mar 1;19(5):1126-38. doi: 10.1158/1078-0432.CCR-12-0989. Epub 2012 Dec 3.

12.

Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.

Edakuni N, Ikuta K, Yano S, Nakataki E, Muguruma H, Uehara H, Tani M, Yokota J, Aizawa H, Sone S.

Oncol Res. 2006;16(5):235-43.

PMID:
17294804
13.

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.

14.

Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.

Nakataki E, Yano S, Matsumori Y, Goto H, Kakiuchi S, Muguruma H, Bando Y, Uehara H, Hamada H, Kito K, Yokoyama A, Sone S.

Cancer Sci. 2006 Mar;97(3):183-91.

15.

The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.

Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, Carson WE 3rd.

Clin Cancer Res. 2007 Nov 1;13(21):6419-28. Epub 2007 Oct 25.

16.

Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma.

Li Q, Wang W, Machino Y, Yamada T, Kita K, Oshima M, Sekido Y, Tsuchiya M, Suzuki Y, Nan-Ya K, Iida S, Nakamura K, Iwakiri S, Itoi K, Yano S.

Cancer Sci. 2015 Jan;106(1):102-7. doi: 10.1111/cas.12575. Epub 2014 Dec 18.

17.

In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.

Watanabe Y, Asano R, Arai K, Shimomura I, Ogata H, Kawaguchi H, Hayashi H, Ohtsuka H, Yoshida H, Katayose Y, Egawa S, Nakanishi T, Umetsu M, Yasui H, Ishida T, Imai K, Kudo T, Unno M, Kumagai I.

Oncol Rep. 2011 Oct;26(4):949-55. doi: 10.3892/or.2011.1382. Epub 2011 Jul 4.

PMID:
21743971
18.

Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.

Barbieri F, Würth R, Favoni RE, Pattarozzi A, Gatti M, Ratto A, Ferrari A, Bajetto A, Florio T.

Biochem Pharmacol. 2011 Nov 15;82(10):1467-77. doi: 10.1016/j.bcp.2011.07.073. Epub 2011 Jul 20.

PMID:
21787763
19.

The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.

Cole GW Jr, Alleva AM, Reddy RM, Maxhimer JB, Zuo J, Schrump DS, Nguyen DM.

J Thorac Cardiovasc Surg. 2005 May;129(5):1010-7.

20.

Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.

Moriya M, Yamada T, Tamura M, Ishikawa D, Hoda MA, Matsumoto I, Klepetko W, Oda M, Yano S, Watanabe G.

Oncol Rep. 2014 Mar;31(3):1109-15. doi: 10.3892/or.2013.2948. Epub 2013 Dec 30.

PMID:
24378576

Supplemental Content

Support Center